For drug makers excited about the prospects of using so-called real-world evidence to expand product indications or fulfill postmarketing requirements, the journey ahead is going to be a slow one.
PDUFA's 'Real-World' Journey Expected To Be Slow Walk
Manufacturers are enthusiastic about the possibility of using real-world evidence to expand product indications. But even with new resource support, they know it's a long road to get there.
